Lee D Y, Park S K, Kim J S
Department of Pediatrics, Chonbuk National University Medical School, Chonju, Korea.
J Clin Endocrinol Metab. 1996 May;81(5):1856-60. doi: 10.1210/jcem.81.5.8626847.
Growth failure appears to be a major problem for nephrotic children who fail to respond to steroid therapy. Recently altered serum insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) profiles are reported in renal failure and glomerulonephritis. In this study, the serum IGFBP profile was evaluated by Western ligand blot and RIA in 22 patients with the nephrotic syndrome. Serum IGFBP-3 was decreased, whereas IGFBP-2 was increased in most patients with the nephrotic syndrome. The mean serum IGFBP-3 level was 2123 +/- 531 ng/mL in active states and was increased to a normal level (3593 +/- 407 ng/mL) in remission states. We also measured serum IGF-I by RIA. The serum concentration of IGF-I (mean +/- SD) was 67.4 +/- 23.2 ng/mL in active states and was increased to 127.1 +/- 21.8 ng/mL in remission states, but was still lower than that in control subjects (180.4 +/- 15.8 ng/mL). IGF-I and IGFBP-3 levels were not correlated with primary renal diseases or the amount of proteinuria. For serum IGF-IGFBP complexes, 150-kDa complexes were significantly decreased in patients with the nephrotic syndrome compared with those in control subjects. In urine from nephrotic syndrome patients, 150- and 50-kDa complexes were found, whereas these complexes did not exist in the urine of control subjects. We speculate that low serum IGF-I and IGFBP-3 levels would be partially due to the increased urinary losses of serum IGF-IGFBP complexes, especially that of 150 kDa, and these changes may contribute to growth failure in persistent nephrotic syndrome.
生长发育迟缓似乎是对类固醇治疗无反应的肾病患儿的一个主要问题。最近有报道称,肾衰竭和肾小球肾炎患者的血清胰岛素样生长因子(IGF)及IGF结合蛋白(IGFBP)水平发生了改变。在本研究中,采用蛋白质免疫印迹法和放射免疫分析法对22例肾病综合征患者的血清IGFBP水平进行了评估。大多数肾病综合征患者血清IGFBP-3水平降低,而IGFBP-2水平升高。活动期患者血清IGFBP-3平均水平为2123±531 ng/mL,缓解期升至正常水平(3593±407 ng/mL)。我们还采用放射免疫分析法测定了血清IGF-I水平。活动期患者血清IGF-I浓度(均值±标准差)为67.4±23.2 ng/mL,缓解期升至127.1±21.8 ng/mL,但仍低于对照组(180.4±15.8 ng/mL)。IGF-I和IGFBP-3水平与原发性肾脏疾病或蛋白尿的量无关。对于血清IGF-IGFBP复合物,与对照组相比,肾病综合征患者的150-kDa复合物显著减少。在肾病综合征患者的尿液中发现了150-kDa和50-kDa复合物,而对照组尿液中不存在这些复合物。我们推测,血清IGF-I和IGFBP-3水平降低可能部分归因于血清IGF-IGFBP复合物,尤其是150 kDa复合物尿排泄增加,这些变化可能导致持续性肾病综合征患者生长发育迟缓。